Cgmp manufacture of two HIV DNA vaccines and one HIV protein vaccine component
Ended Awarded Last action
- Contract number
- 75N91020F00027
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,907,716
Award facts
- Contract value 100% obligated
- $5,907,716.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21703, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Terminate for Convenience | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $249,143 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $676,199 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $654,969 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $4,149,106 | |
| Other Administrative Action | $9,000 | |
| Original award | $169,299 |
Show all 22
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on September 25, 2020, with a ceiling value of $5.9 million for current Good Manufacturing Practice (CGMP) manufacture of two HIV DNA vaccines and one HIV protein vaccine component.
Place of performance is Frederick, Maryland. The order was completed on September 24, 2025. Pricing is cost plus fixed fee, with no set-aside applied. Leidos Biomedical Research Inc. operates as a Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute and National Institutes of Health, delivering biomedical research and facilities support services to federal agencies.
Quick answers
Who was awarded contract 75N91020F00027?
75N91020F00027 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 25, 2020.
How much is contract 75N91020F00027 worth?
The government has obligated $5,907,716 on 75N91020F00027.
Is contract 75N91020F00027 an order under another contract?
Yes. 75N91020F00027 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00027 competed?
The extent of competition for 75N91020F00027 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award